SpyGlass Pharma is taking a major step toward changing how eye diseases are treated by filing for a $100 million initial public offering. Based in California, this biotechnology company is in the final stages of testing a new way to deliver medicine for chronic eye conditions. Instead of patients having to use daily eye drops, SpyGlass has created a system that delivers medicine automatically for up to three years. They plan to list their shares on the Nasdaq stock market under the ticker symbol SGP.<\/p>\n
The company\u2019s most advanced product is designed specifically for people who have glaucoma and are already undergoing cataract surgery. During the routine operation, a surgeon implants a special lens that has tiny medicine pads attached to it. These pads slowly release a proven drug called bimatoprost to keep eye pressure at healthy levels. This is a huge deal because many patients struggle to remember their daily drops, which can lead to permanent vision loss if the pressure isn\u2019t controlled.<\/p>\n
Recent tests have shown very positive results for this new technology. In early trials, patients saw their eye pressure drop by about 37% over a three-year period. Even more impressive is that almost every patient in the study was able to stop using their regular eye drops entirely. The company is also working on a second version of the device that can be used for people who have already had cataract surgery in the past.<\/p>\n
SpyGlass intends to use the money raised from the IPO to finish its final Phase 3 clinical trials. These trials are the last big hurdle before the company can ask the government for permission to sell the product. They also recently hired a new Chief Financial Officer with experience in public companies to help them navigate this transition. If successful, this technology could offer a much simpler and more reliable way for millions of people to protect their eyesight.<\/p>\n","protected":false},"excerpt":{"rendered":"
SpyGlass Pharma is taking a major step toward changing how eye diseases are treated by filing for a $100 million\u2026<\/p>\n","protected":false},"author":294,"featured_media":105477,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[73],"tags":[],"class_list":["post-105476","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-us-markets"],"reading_time":"2 min read","_links":{"self":[{"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/posts\/105476","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/users\/294"}],"replies":[{"embeddable":true,"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/comments?post=105476"}],"version-history":[{"count":0,"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/posts\/105476\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/media\/105477"}],"wp:attachment":[{"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/media?parent=105476"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/categories?post=105476"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/tags?post=105476"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}